Submit Deal

MERZ THERAPEUTICS

Summary

Merz Therapeutics is a pharmaceutical company helping people who suffer from movement disorders, neurodegenerative conditions or liver disease.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 148 M

Avg. Deal Size£ 148 M

Market Context

Senior Management

Stefan König
CEO
Michael Schwaninger
CFO
Jörg Bergler
Merz Group COO

Sort

baker mckenzie

HQ - Chicago

legal advisors (1)

1 Shared Deal

1 Opposite

£ 148 M

Total Value

ernst & young

HQ - London

financial advisors (1)

1 Shared Deal

1 Opposite

£ 148 M

Total Value

ducera partners

financial advisors (1)

1 Shared Deal

1 Opposite

£ 148 M

Total Value

leerink partners

financial advisors (1)

1 Shared Deal

1 Opposite

£ 148 M

Total Value

perella weinberg partners

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 148 M

Total Value

deloitte

HQ - London

tax advisors (1)

1 Shared Deal

1 For

£ 148 M

Total Value

freshfields bruckhaus deringer

HQ - London

legal advisors (1)

1 Shared Deal

1 For

£ 148 M

Total Value

morgan stanley

HQ - New York

financial advisors (1)

1 Shared Deal

1 For

£ 148 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy